Tenon Medical (TNON) projects 90% Q4 and 20% full-year 2025 revenue growth
Rhea-AI Filing Summary
Tenon Medical, Inc. reported preliminary unaudited revenue ranges showing strong growth for 2025. Fourth quarter 2025 revenue is expected between $1.45 million and $1.48 million, which the company says is about 90% higher year over year compared with the fourth quarter of 2024.
For full year 2025, Tenon expects unaudited revenue between $3.91 million and $3.94 million, representing roughly 20% year-over-year growth versus 2024. The company plans to release full financial results after market close on March 19, 2026 and will host a conference call that day at 4:30 p.m. Eastern Time to discuss the results in more detail.
Positive
- Strong revenue acceleration: Tenon expects Q4 2025 unaudited revenue of $1.45–$1.48 million, approximately 90% higher year-over-year, and full-year 2025 revenue of $3.91–$3.94 million, about 20% above 2024.
Negative
- None.
Insights
Tenon preannounces strong 2025 revenue growth and sets earnings call.
Tenon Medical reaffirmed preliminary 2025 revenue ranges that indicate rapid expansion. Fourth quarter 2025 unaudited revenue of
For the 2025 fiscal year, unaudited revenue of
The company scheduled its detailed results release for after market close on
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission File Number) | (IRS Employer | ||
| of incorporation) | Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
(
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The Stock Market LLC | ||||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On February 5, 2026, Tenon Medical, Inc., a Delaware corporation (the “Company”), issued a press release announcing unaudited revenue for the fourth quarter of 2025 totaling $1.45 to $1.48 million, which represents an approximately 90% increase in revenue year-over-year, as compared to the fourth quarter of 2024 fiscal year, as well as unaudited revenue for the 2025 fiscal year totaling $3.91 to $3.94 million, which represents an approximately 20% increase in revenue year-over-year, as compared to 2024 fiscal year.
The Company also stated in the press release that it plans to release financial results for the fourth quarter and full year 2025 ended December 31, 2025 after market close on Thursday, March 19, 2026, and hold a conference call on the same day at 4:30 p.m. (Eastern Time) to discuss its financial results in further details.
Item 8.01 Other Events.
A copy of the press release referenced in Item 2.02 of this Current Report on Form 8-K is as Exhibit 99.1 to this Current Report on Form 8-K.
The disclosure under Item 8.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information provided herein shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
1
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are being filed herewith:
| Exhibit No. | Description | |
| 99.1 | Press Release of Tenon Medical, Inc., dated February 5, 2026. | |
| 104 | Cover Page Interactive Data File (embedded with the Inline XBRL document). |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: February 6, 2026 | TENON MEDICAL, INC. | |
| (Registrant) | ||
| By: | /s/ Steven M. Foster | |
| Name: | Steven M. Foster | |
| Title: | Chief Executive Officer and President | |
3
Exhibit 99.1
Tenon Medical, Inc. Sets Date for Fourth Quarter
and Full Year 2025 Earnings, Reaffirms
Expected Revenues
Fourth Quarter 2025 Revenue of $1.45 to $1.48
Million, representing growth of ~90% year over
year
Full Year 2025 Revenue of $3.91 to $3.94 Million, representing growth of ~20% year over year
Los Gatos, CA, February 5, 2026 - Tenon Medical, Inc. (NASDAQ: TNON) (“Tenon” or the “Company”), a company redefining care for patients suffering from sacro-pelvic disorders, today announced plans to release financial results for the fourth quarter and full year 2025 ended December 31, 2025 after market close on Thursday, March 19, 2026. The Company will also hold a conference call on the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with its covering analysts.
|
Date: |
Thursday, March 19, 2026 |
| Time: | 4:30 p.m. Eastern time |
| Dial-in: | 1-877-407-0792 |
| International Dial-in: | 1-201-689-8263 |
| Webcast: | TNON Conference Call |
Please dial in at least 10 minutes before the start of the call to ensure timely participation.
An audio playback of the call will be available through April 2, 2026, on Tenon’s Investor Relations website at http://ir.tenonmed.com/ or via telephone replay by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (International). The access code will be 13758268.
About Tenon Medical, Inc.
Tenon Medical, Inc., a medical device company formed in 2012, has developed The Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Since the national launch of the Catamaran SI Joint Fusion System in October 2022, Tenon is focused on three commercial opportunities with its System in the SI Joint market which include: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants and 3) Augmenting spinal fusion. For more information, please visit www.tenonmed.com.
The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAILTM, and SImmetry+ are also trademarks of Tenon Medical, Inc.
Investor Contact
Shannon Devine
MZ North America
203-741-8811
tenon@mzgroup.us
FAQ
What preliminary fourth quarter 2025 revenue did Tenon Medical (TNON) report?
What are Tenon Medical’s preliminary full year 2025 revenues and growth versus 2024?
When will Tenon Medical (TNON) release full fourth quarter and 2025 results?
When is Tenon Medical’s earnings conference call for fourth quarter and full year 2025?
How can investors access Tenon Medical’s March 19, 2026 earnings call replay?
What does Tenon Medical, Inc. do in the medical device market?
